BlackRock’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.17B | Buy |
20,445,212
+626,911
| +3% | +$34.3M | 0.02% | 674 |
|
|
2026
Q1 | $1.12B | Buy |
19,818,301
+683,193
| +4% | +$39.8M | 0.02% | 633 |
|
|
2025
Q4 | $1.14B | Sell |
19,135,108
-2,910,942
| -13% | -$158M | 0.02% | 634 |
|
|
2025
Q3 | $1.19B | Sell |
22,046,050
-1,955,625
| -8% | -$112M | 0.02% | 604 |
|
|
2025
Q2 | $1.32B | Buy |
24,001,675
+222,676
| +0.9% | +$13.1M | 0.03% | 532 |
|
|
2025
Q1 | $1.68B | Buy |
23,778,999
+265,883
| +1% | +$17.9M | 0.04% | 431 |
|
|
2024
Q4 | $1.55B | Buy |
23,513,116
+889,613
| +4% | +$59.6M | 0.03% | 468 |
|
|
2024
Q3 | $1.59B | Sell |
22,623,503
-114,846
| -0.5% | -$9.6M | 0.03% | 458 |
|
|
2024
Q2 | $1.87B | Buy |
22,738,349
+8,259,559
| +57% | +$688M | 0.04% | 377 |
|
|
2024
Q1 | $1.26B | Sell |
14,478,790
-202,854
| -1% | -$18.2M | 0.03% | 515 |
|
|
2023
Q4 | $1.42B | Buy |
14,681,644
+74,457
| +0.5% | +$6.59M | 0.04% | 444 |
|
|
2023
Q3 | $1.29B | Buy |
14,607,187
+591,722
| +4% | +$52.6M | 0.04% | 438 |
|
|
2023
Q2 | $1.21B | Sell |
14,015,465
-623,111
| -4% | -$58.6M | 0.03% | 467 |
|
|
2023
Q1 | $1.42B | Buy |
14,638,576
+98,385
| +0.7% | +$10.2M | 0.04% | 407 |
|
|
2022
Q4 | $1.5B | Buy |
14,540,191
+252,332
| +2% | +$23.7M | 0.05% | 380 |
|
|
2022
Q3 | $1.21B | Sell |
14,287,859
-129,242
| -0.9% | -$11.5M | 0.04% | 425 |
|
|
2022
Q2 | $1.19B | Buy |
14,417,101
+459,041
| +3% | +$36.5M | 0.04% | 444 |
|
|
2022
Q1 | $1.08B | Buy |
13,958,060
+56,879
| +0.4% | +$4.76M | 0.03% | 555 |
|
|
2021
Q4 | $1.23B | Sell |
13,901,181
-1,419,618
| -9% | -$117M | 0.03% | 520 |
|
|
2021
Q3 | $1.18B | Buy |
15,320,799
+2,425,231
| +19% | +$191M | 0.03% | 514 |
|
|
2021
Q2 | $1.08B | Sell |
12,895,568
-1,038,589
| -7% | -$82.3M | 0.03% | 564 |
|
|
2021
Q1 | $1.05B | Sell |
13,934,157
-780,003
| -5% | -$63.7M | 0.03% | 561 |
|
|
2020
Q4 | $1.29B | Buy |
14,714,160
+78,638
| +0.5% | +$6.23M | 0.04% | 438 |
|
|
2020
Q3 | $1.11B | Sell |
14,635,522
-1,328,289
| -8% | -$134M | 0.04% | 421 |
|
|
2020
Q2 | $1.97B | Buy |
15,963,811
+1,368,101
| +9% | +$136M | 0.08% | 236 |
|
|
2020
Q1 | $1.23B | Buy |
14,595,710
+1,537,729
| +12% | +$132M | 0.06% | 297 |
|
|
2019
Q4 | $1.1B | Buy |
13,057,981
+157,268
| +1% | +$11.9M | 0.04% | 428 |
|
|
2019
Q3 | $870M | Buy |
12,900,713
+40,642
| +0.3% | +$3.13M | 0.04% | 483 |
|
|
2019
Q2 | $1.1B | Buy |
12,860,071
+196,702
| +2% | +$16.8M | 0.05% | 398 |
|
|
2019
Q1 | $1.12B | Sell |
12,663,369
-915,193
| -7% | -$84.8M | 0.05% | 375 |
|
|
2018
Q4 | $1.16B | Sell |
13,578,562
-544,751
| -4% | -$51.8M | 0.06% | 318 |
|
|
2018
Q3 | $1.37B | Buy |
14,123,313
+1,002,054
| +8% | +$100M | 0.06% | 313 |
|
|
2018
Q2 | $1.24B | Buy |
13,121,259
+323,227
| +3% | +$28.3M | 0.06% | 329 |
|
|
2018
Q1 | $1.04B | Sell |
12,798,032
-21,712
| -0.2% | -$1.86M | 0.05% | 390 |
|
|
2017
Q4 | $1.14B | Buy |
12,819,744
+937,183
| +8% | +$81.5M | 0.05% | 349 |
|
|
2017
Q3 | $1.11B | Buy |
11,882,561
+481,601
| +4% | +$42.6M | 0.06% | 343 |
|
|
2017
Q2 | $1.04B | Buy |
11,400,960
+335,508
| +3% | +$30.5M | 0.05% | 359 |
|
|
2017
Q1 | $971M | Buy |
11,065,452
+10,909,162
| +6,980% | +$971M | 0.05% | 365 |
|
|
2016
Q4 | $12.9M | Buy |
156,290
+8,187
| +6% | +$704K | 0.02% | 669 |
|
|
2016
Q3 | $13.7M | Buy |
148,103
+10,780
| +8% | +$1.02M | 0.02% | 647 |
|
|
2016
Q2 | $10.7M | Sell |
137,323
-18,261
| -12% | -$1.55M | 0.02% | 685 |
|
|
2016
Q1 | $12.8M | Buy |
155,584
+7,276
| +5% | +$592K | 0.02% | 611 |
|
|
2015
Q4 | $15.5M | Buy |
148,308
+48,959
| +49% | +$5.11M | 0.02% | 586 |
|
|
2015
Q3 | $10.5M | Sell |
99,349
-44,498
| -31% | -$5.94M | 0.02% | 623 |
|
|
2015
Q2 | $19.7M | Sell |
143,847
-129,588
| -47% | -$16.1M | 0.03% | 521 |
|
|
2015
Q1 | $34.1M | Buy |
273,435
+79,616
| +41% | +$8.44M | 0.05% | 408 |
|
|
2014
Q4 | $17.5M | Sell |
193,819
-95,557
| -33% | -$7.95M | 0.03% | 561 |
|
|
2014
Q3 | $20.9M | Sell |
289,376
-19,909
| -6% | -$1.31M | 0.03% | 502 |
|
|
2014
Q2 | $19.2M | Sell |
309,285
-97,498
| -24% | -$5.89M | 0.03% | 516 |
|
|
2014
Q1 | $27.7M | Buy |
406,783
+188,063
| +86% | +$13.9M | 0.04% | 424 |
|
|
2013
Q4 | $15.4M | Buy |
218,720
+136,828
| +167% | +$9.29M | 0.03% | 568 |
|
|
2013
Q3 | $5.91M | Buy |
81,892
+26,970
| +49% | +$1.79M | 0.01% | 730 |
|
|
2013
Q2 | $3.06M | Buy |
+54,922
| New | +$3.42M | 0.01% | 841 |
|
Other funds holding BMRN
VPC
BlackRock's BMRN Position: Q2 2026 in Review
BlackRock increased its BioMarin Pharmaceuticals (BMRN) stake by 3.2% in Q2 2026, buying an estimated $34.3M and bringing the position to 20,445,212 shares worth $1.17B. The position accounts for 0.02% of the portfolio, ranked #674.
BlackRock first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.97B in Q2 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- BlackRock held 20,445,212 shares of BioMarin Pharmaceuticals worth $1.17B as of Q2 2026.
- BlackRock bought 626,911 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $34.3M.
- BioMarin Pharmaceuticals made up 0.02% of BlackRock's portfolio in Q2 2026, its #674 holding.
- BlackRock first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- BlackRock's BioMarin Pharmaceuticals position peaked at $1.97B in Q2 2020.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.